Avalyn Pharma
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
105 W 1st St, Boston, Massachusetts, 021...Phone Number
(206) 707-0340Website
www.avalynpharma.comRevenue
-Industry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Avalyn Pharma
Avalyn is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILD). ILDs are characterized by pulmonary scarring, a decline in lung function, reduced exercise capacity and quality of life, and increased mortality risk. Currently approved therapeutic options slow disease progression but are associated with significant side effects, which restrict their use and dosing. Avalyn is developing a pipeline of inhaled medicines to reduce systemic exposure and deliver the medication directly to the disease site. AP01, Avalyns lead candidate, is a Phase 2b-ready inhaled formulation of pirfenidone optimized for direct lung delivery via inhalation. In a recent clinical study of two doses assessed in 91 individuals with IPF, AP01 demonstrated the potential to improve efficacy and safety over existing therapy.Explore more
Avalyn Pharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Avalyn Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Avalyn Pharma is spiking on competitors!
Earning: See what the market has to say on Avalyn Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Avalyn Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Avalyn Pharma has new funding data
Avalyn Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Avalyn Pharma
Click to see if Avalyn Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Avalyn Pharma launches new products
Recommended Actions
Find VP level buyers at Avalyn Pharma
Find 2 more new buyers
Compare Similar Companies to Avalyn Pharma
Compare insights from companies similar to Avalyn Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Avalyn Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Avalyn Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Avalyn Pharma.
Avalyn Pharma financials insights
Gather financial insights about Avalyn Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Private Equity
$2.2M
2012
Unspecified
$1.2M
2017
Private Equity
$16.6M
Series A
$62M
2020
Series B
$35.5M
2023
Series C
$175M
2025
Series D
$100M
Avalyn Pharma Tech Stack
A closer look at the technologies used by Avalyn Pharma
See more technologies
Most Recent Scoops
Open Position
Open Position
Person-Based
Earnings, Finance
Open Position
Open Position
Avalyn Pharma News & Media
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Directors (the “Board”). Dr. Meyer most recently served as PrinciAvalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Avalyn Pharma Inc. (AVLN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:50 PM EDTCompany ParticipantsLyn Baranowski - CEO,...Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 14, 2026, at 1:50-2:25 p.m. ET.Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Avalyn Pharma
Sign Up For FreeTo access detailed company insights
Avalyn is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILD). ILDs are characterized by pulmonary scarring, a decline in lung function, reduced exercise capacity and quality of life, and increased mortali... Read More
